FDA warned an online pharmacy for selling injectable semaglutide without prescriptions

On September 23, 2026, the FDA's Center for Drug Evaluation and Research sent a warning letter to Online Generic Medicine, operator of www.onlinegenericmedicine.com, for introducing unapproved and misbranded injectable semaglutide products into interstate commerce. Violations were documented during reviews of the site on August 26 and September 2, 2026.

The example product was semaglutide marketed as 'Semanat Injection (Semaglutide)', described on the site as 'a potent glucagon-like peptide-1 (GLP-1) receptor agonist' for managing blood sugar in type 2 diabetes and supporting weight management. FDA noted the approved semaglutide products — Ozempic and Wegovy — are prescription-only and carry the agency's strongest boxed warning, for thyroid C-cell tumor risk. Selling the unapproved copy without requiring a prescription misbranded the drug under sections 502(f)(1) and 503(b)(1) of the FD&C Act.

FDA warned that drugs which circumvent regulatory safeguards may be contaminated, counterfeit, or contain varying or different ingredients, and that injectables bypass many of the body's natural defenses — risking serious, life-threatening conditions such as septicemia or sepsis. The agency ordered the site to stop offering unapproved and misbranded drugs to US consumers and to respond within 15 business days with corrective steps.

A public FDA warning letter; respond within 15 business days or risk seizure, injunction and import detention without further notice.

The site marketed a prescription GLP-1 drug straight to consumers with no prescription, so no clinician screened contraindications.

Unapproved copies can be contaminated, counterfeit or wrongly dosed — with none of the assurances of approved semaglutide.

Injectables bypass the body's natural defenses, so a contaminated product can cause life-threatening sepsis.

A prescription requirement is a safety system, not paperwork: selling an injectable straight to consumers strips away the diagnosis, dosing and sterility checks approval exists to guarantee.

The letter is public on fda.gov. FDA said failure to correct could bring regulatory or legal action without further notice, including seizure and injunction, and that products from overseas sellers may be detained or refused admission, with regulators in the country of operation notified.